Saline Enhanced Radiofrequency (SERF) Ablation for Refractory VT
This study is testing a new treatment called Saline Enhanced Radiofrequency (SERF) Ablation using the Durablate catheter for people with Refractory Ventricular Tachycardia (VT). VT is a fast, abnormal heart rhythm that hasn't responded to other treatments. The Durablate catheter delivers heated saline to specific areas of the heart to correct these rhythms. You might be able to join if you are 18 or older, have structural heart disease, and have experienced recurrent VT that hasn't improved with other therapies. The study will look at how well the treatment works right after the procedure and again after 6 months. The current status of this study is unclear, but it plans to enroll 130 participants.
- Study design
- This is an interventional study, meaning participants will receive the treatment being tested. It is a single-group study, so all participants will receive the SERF Ablation.
- What's involved
- You would undergo a study ablation procedure. Follow-up visits will occur at 7 days, 30 days, 3 months, and 6 months after the ablation.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months after the ablation procedure to assess long-term effectiveness.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
At a glance
Conditions
NCT05337241
Where you'd take part
This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Intermountain Healthcare
Salt Lake City, Utahstudy coordinator listed
Recruiting
Medical University of South Carolina
Charleston, South Carolinastudy coordinator listed
Not yet recruiting
Montreal Heart Institute - Institut de Cardiologie de Montréal
Montreal, Quebec, Canadastudy coordinator listed
Recruiting
Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec, Canadastudy coordinator listed
Not yet recruiting
University of Alabama at Birmingham
Birmingham, Alabamastudy coordinator listed
Not yet recruiting
Vanderbilt University Medical Center
Nashville, Tennesseestudy coordinator listed
Not yet recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvaniano site contact published
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Michael Curley, PhD · STUDY_DIRECTOR · Thermedical, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Primary Efficacy (Acute Interim)At end of ablation procedure (ablation procedure occurs on a single day)
Percentage of target clinical VTs that are non-inducible at end of the study ablation procedure (if PES performed at procedure conclusion)
- Primary Efficacy (Long Term)6 month post ablation
Percentage of subjects who are free from recurrent monomorphic VT